Surprisingly, our own and other data have demonstrated that MM patients with low levels of “oncogenic” c-Jun have a shorter overall and event-free survival when compared to patients with normal or high levels of c-Jun. The gene discussed is JUN; the disease is Miyoshi myopathy.